# Source: DailyMed — PRIALT (ziconotide) Prescribing Information

**Type:** source
**Status:** Useful
**Confidence:** High
**Source Type:** Government Record
**URL:** https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1
**Publisher:** U.S. National Library of Medicine / DailyMed (FDA-sourced label)
**Accessed:** 2026-06-19
**Updated:** 2026-06-19

## Summary

FDA-approved prescribing information for Prialt (ziconotide), hosted on DailyMed, the NLM's official drug labeling repository. Establishes the drug's composition, approved indication, delivery route, warnings, and initial U.S. approval year (2004).

## Useful Claims

- Prialt contains ziconotide, a synthetic equivalent of a naturally occurring conopeptide from Conus magus.
- Initial U.S. approval: 2004.
- Approved indication: management of severe chronic pain in patients who require intrathecal therapy and are refractory to or intolerant of other treatments.
- Administered by continuous intrathecal infusion via an implanted or external pump.
- Carries serious psychiatric and neurological risk warnings.

## Reliability Notes

Authoritative government source (NLM/FDA); DailyMed labels are the current, approved regulatory documents for the drug. This is primary for all approved-use and regulatory facts about Prialt. Does not cover the discovery history or commercial licensing chain.

## Related Pages

- [Conotoxins and Prialt](conotoxins-and-prialt.md)